JAMA ophthalmology۲۰۲۵گزارش موردنمایه شده در PubMed
Will Bruening, Sean Kim, Steven Yeh, Pukhraj Rishi, Christopher D Conrady
چکیده
Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies. However, more rare adverse events…
متن کامل چکیده در سایت ناشر در دسترس است.
DOI: 10.1001/jamaophthalmol.2024.5889